Recent Updates
Recently added Catalysts

Trevena, Inc.

TRVNFDA catalysts, PDUFA dates & pipeline intelligence
$0
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TRVN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
977.00
Value Traded
0.49
Short % Float
-
-100%5 Year
-99.94%All Time

Cash Data

Unlock TRVN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
812.80 K
Insiders
0.00%
Institutions
0.10%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every TRVN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TRVN Catalyst Timeline

Dated clinical, regulatory and corporate events for Trevena, Inc.

Unlock the full TRVN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TRVN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-12-31TRV045 Optimized Phase 1 data readout Phase 1
Unlock 3 more TRVN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
0
Drugs Scored
rNPV / MCap
Top Drug
Top 98%
Small Cap
(rank 705 of 719)
Percentile Rank
Showing 3 of 8 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
TRV130 Small MoleculesMarketedNCT02083315Acute PainApproved COMPLETED 1,131Aug 1, 2013
Oliceridine Small MoleculesMarketedNCT02820324Acute PainApproved COMPLETED 825Jan 1, 2017
TRV130 Small MoleculesMarketedNCT02335294PainApproved COMPLETED 200Aug 1, 2015
Unlock the TRVN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every TRVN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
TRV045 CNS disorders2023-11-14no drug-related adverse events, no serious adverse events and no study drug-related discontinuations reportedRead MoreTrevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action andRead More
Scroll for more · summaries link to the source press release
Unlock every TRVN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TRVN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Shin BarryOfficer (SVP, CFO)Sell -31,785 873,056 held$0.41 06/28/2022
Unlock the full TRVN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
NEA Management Company, LLC 0.1 % 4.69 M 3.81 M
Unlock every fund holding TRVN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TRVN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TRVN ownership
Insider and institutional ownership, quarter by quarter.

TRVN Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
3.3K
Shares Sold Short
+1.5% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
86
Avg Daily Volume
the average used for days to cover
Unlock TRVN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock TRVN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TRVN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TRVN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TRVN ranks across every disease it competes in

Competitive Position is a premium feature
See how TRVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TRVN News

TRVN
Nov 7, 2024
TRVNGeneral
▲ +14.2%on this news

Trevena Reports Third Quarter 2024 Results and Provides Business Update CHESTERBROOK, Pa.

Trevena Reports Third Quarter 2024 Results and Provides Business Update CHESTERBROOK, Pa., November 7, 2024 (GLOBE NEWSWIRE) -Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centra

Read more →
TRVN
Oct 4, 2024
TRVNGeneral
▲ +15.2%on this news· ran to -63% by day 3

Trevena Announces Receipt of Nasdaq Delisting Notification -- CHESTERBROOK, Pa.

Receipt of Nasdaq Delisting Notification CHESTERBROOK, Pa., October 4, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders

Read more →
TRVN
Aug 8, 2024
TRVNGeneral
▲ +9%on this news

Trevena Reports Second Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained lo

Trevena Reports Second Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of

Read more →
TRVN
Aug 8, 2024
TRVNGeneral
▲ +9%on this news

Trevena Announces Reverse Stock Split -- CHESTERBROOK, Pa.

Trevena Announces Reverse Stock Split Pa., August 8, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced

Read more →
TRVN
Jul 8, 2024
TRVNGeneral

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing Trevena expects to receive a non-dilutive $2 million tranche and may be el

$2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINYVK US partnering and commercializat

Read more →
TRVN
May 15, 2024
TRVNGeneral

Trevena Reports First Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK st

Reports First Quarter 2024 Results and Provides Business Update novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 Pa.

Read more →
TRVN
Apr 1, 2024
TRVNGeneral
▼ -13%on this news

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies

Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies announces reduction of OLINVYK commercial support and review of alternat

Read more →
TRVN
Jan 8, 2024
TRVNConferences/Events

INNOVATING FOR PATIENTS Nasdaq: TRVN I January 2024 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the “Co

Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications. ADVERSE REACTIONS Adverse reactions are

Read more →
TRVN
Dec 27, 2023
TRVNGeneral

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise CHESTERBROOK, Pa.

Trevena Inc. Announces $4 Million Concurrent Private Placement and CHESTERBROOK, Pa., Dec. 27, 2023 -- Trevena Inc. ("Trevena" or the "Company") (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ce

Read more →
TRVN
Nov 14, 2023
TRVNPhases

Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and

Third Quarter 2023 Results and Provides Business Update announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS favorable safety and tolerability data from TRV045 POC studies for OLINVYK presented at

Read more →
TRVN
Oct 2, 2023
TRVNConferences/Events

INNOVATING FOR PATIENTS Nasdaq: TRVN I October 2023 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the “Co

Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications. ADVERSE REACTIONS Adverse reactions are

Read more →
TRVN
Sep 6, 2023
TRVNConferences/Events
▲ +14.3%on this news

INNOVATING FOR PATIENTS Nasdaq: TRVN I September 2023 Forward - Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (t he "Comp

INNOVATING FOR PATIENTS Nasdaq: TRVN I September 2023 Forward - Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (t he "Company" or "we"), they are forward - looking statements reflec

Read more →
TRVN
Aug 14, 2023
TRVNPhases
▲ +5.8%on this news

Trevena Reports Second Quarter 2023 Results and Provides Business Update Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV04

Second Quarter 2023 Results and Provides Business Update database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing w

Read more →
TRVN
Jul 20, 2023
TRVNGeneral

Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors CHESTERBROOK, Pa.

Appoints Mark Corrigan, M.D. to Board of Directors CHESTERBROOK, Pa., July 20, 2023, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system

Read more →
TRVN
Jun 26, 2023
TRVNPhases

Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admi

New Topline OLINVYK Data Highlighting per Admission from ARTEMIS Real-World Outcomes Study patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated w

Read more →
TRVN
May 30, 2023
TRVNGeneral

Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones CHESTERBROOK, Pa.

Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nerv

Read more →
TRVN
May 15, 2023
TRVNFDA Updates
▼ -12.6%on this news

Trevena Reports First Quarter 2023 Results and Provides Business Update OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company's China partner Jiangsu Nhwa Pharmaceutical Comp

Trevena Reports First Quarter 2023 Results and Provides Business Update OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company's China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilut

Read more →
TRVN
May 9, 2023
TRVNGeneral
▼ -43.1%on this news· ran to -57% by day 3

Trevena to Release First Quarter 2023 Financial Results on

Trevena to Release First Quarter 2023 Financial Results on May 15, 2023 Company to host a Conference Call & Webcast at 8:00 a.m. ET CHESTERBROOK, Pa., May 9, 2023 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of

Read more →
TRVN
May 8, 2023
TRVNFDA Updates
▲ +393.7%on this newsshared move

Trevena Announces Approval of OLINVYK in China Trevena's partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangs

Approval of OLINVYK in China partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) $3 million milestone to Trevena from Jiangsu Nhwa million to Trevena expected on first commercial sale in China, based on ex-US Royalty-Based Fina

Read more →
TRVN
Mar 30, 2023
TRVNPhases

Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of

Initial Topline OLINVYK Data from Real-World Clinical Outcomes Study patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMI

Read more →

About Trevena, Inc.

Pa, 19087 trevena.com
Headquarters955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, 19087, United States
Founded2014
BIOPHARMAWATCH ELITE
Trade the next TRVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime